PMTA Ingredient Docs: What First Authorized Pouches Reveal

On December 19, 2025, the FDA issued Marketing Granted Orders for six on! PLUS nicotine pouch products from Helix Innovations, according to the FDA Center for Tobacco Products announcement. These were the first nicotine pouch PMTA authorizations in FDA history, completing a streamlined pilot review that began in September 2025. For manufacturers with applications pending, or building one now, the question is the same: what did it take to get there?

The product formulations matter. The clinical data matters. But so does something that gets far less attention in the post-authorization analysis: the PMTA ingredient documentation package. Specifically, what FDA accepted as sufficient proof that the nicotine source meets the standard required for a marketing authorization.

Why These Authorizations Set the Bar

The on! PLUS authorizations are the first real data points the industry has had on what a technically complete nicotine pouch PMTA looks like from the inside. Before December 2025, manufacturers were navigating a process with no completed reference cases. The FDA's draft guidance, the proposed TPMP rule (Federal Register, March 2023, docket FDA-2023-N-0001), and the Section 904 ingredient submission requirements described the standards in principle. The authorizations showed what that looks like in practice.

The PMTA pilot program was designed to evaluate a defined subset of pouch products against FDA's scientific standard. Helix Innovations prepared applications that satisfied FDA reviewers across every required domain: product characterization, toxicological assessment, human behavioral data, and manufacturing controls. The manufacturing controls section is where ingredient documentation lives. That section does not get through review on assertions alone.

According to the proposed TPMP rule and FDA's published TPSAC backgrounder (May 2023), the manufacturing data FDA evaluates includes: pre-production design validation records, master manufacturing records (MMR), production records, ingredient specifications with corresponding certificates of analysis, and traceability documentation from raw material through finished product.

For pouches, nicotine is the active ingredient and the ingredient with the highest regulatory scrutiny. Every claim about nicotine content, purity, and uniformity in the application traces back to the ingredient supplier's documentation.

What FDA Reviews When It Reviews Your Nicotine Ingredient

The ingredient section of a PMTA is not a checkbox. FDA reviewers want to understand the nicotine source, its chemical characterization, how its quality is controlled batch-to-batch, and how those controls connect to the consistency claims made about the finished product.

Specifically, the documentation that supports a successful PMTA ingredient section includes:

Purity and characterization data. For a nicotine pouch filing, FDA expects nicotine purity documentation consistent with pharmaceutical-grade standards. That means USP/EP-grade nicotine at 99.5%+ purity with a complete impurity profile: nornicotine, anabasine, anatabine, myosmine, and cotinine all individually quantified. Round numbers ("greater than 99%") raise questions. Specific batch data from accredited laboratories does not.

Batch-specific COAs. Template certificates are not acceptable as PMTA support. Each batch referenced in the application needs its own certificate of analysis, identifying the batch number, analysis date, testing method, and results. If a manufacturer references nicotine from multiple production batches across their stability study, each batch needs documented purity data from that specific lot.

Impurity profile consistency. One of the things FDA evaluated in the on! PLUS review was whether the nicotine source produced consistent impurity profiles across batches. A supplier whose minor alkaloid content swings from 0.3% to 2.1% between deliveries is a liability in a PMTA. Consistency is not just a quality concern. It is a regulatory credibility problem.

Source traceability. Under Section 904 of the Tobacco Control Act, manufacturers are required to submit ingredient listings. The nicotine source is a listed ingredient, and FDA expects documentation of its origin. Seed-to-shipment traceability covers the full chain: what tobacco varieties were grown where, how they were extracted, and how the purification chain was controlled. That documentation supports both the Section 904 submission and the manufacturing controls section of the PMTA. STC certification provides an independent audit trail that FDA reviewers can evaluate without having to take the manufacturer's word for it.

Tobacco Product Master Files (TPMF). The FDA allows ingredient and component suppliers to file a Tobacco Product Master File containing their confidential formulation and quality data. A manufacturer whose nicotine supplier has filed a TPMF can reference that file in their PMTA, allowing FDA reviewers to access the supplier's full technical package without it being disclosed to the applicant. For nicotine ingredient suppliers operating at the scale where multiple manufacturers rely on their product, a TPMF is the documentation infrastructure that makes cross-application consistency demonstrable to FDA.

The TPMP Framework: Still the Standard, Even Without a Final Rule

The FDA's proposed Tobacco Product Manufacturing Practice (TPMP) rule was published in the Federal Register on March 10, 2023 (docket FDA-2023-N-0001). As of early 2025, the rule was reclassified to "Long Term Action" on the Unified Regulatory Agenda, meaning no final rule is expected in the near term.

That does not change what FDA expects to see in a PMTA.

The TPMP rule described what FDA considers good manufacturing practice for tobacco and nicotine products: design controls, pre-production validation, personnel and training standards, facility requirements, quality systems, and batch traceability. These are not future requirements awaiting a final rule. They are the implicit standard against which FDA reviewers evaluate manufacturing controls in every PMTA submission. The on! PLUS authorizations demonstrated that meeting this standard is possible. They also confirmed what was already known: the manufacturers who get through review are the ones who built these systems before anyone made them mandatory.

For a nicotine pouch manufacturer building toward a PMTA, the practical question is not whether TPMP will be finalized. It is whether your manufacturing controls documentation, including your ingredient supplier documentation, would satisfy a reviewer who is benchmarking your application against those standards.

What This Means for Choosing a Nicotine Supplier

Manufacturers seeking PMTA authorization need a nicotine supplier whose documentation infrastructure supports the PMTA documentation package. That narrows the field considerably.

A supplier providing template COAs rather than batch-specific data is not PMTA-ready. A supplier who cannot produce traceability records from tobacco origin through the finished ingredient is not PMTA-ready. A supplier whose impurity profiles are inconsistent batch-to-batch creates a materials characterization problem that will surface in FDA review.

The criteria that distinguish a PMTA-ready nicotine supplier from a commodity ingredient provider are specific. A supplier with a filed TPMF and five consecutive batch COAs on hand can typically close the ingredient documentation section of a PMTA in weeks, not months. These are the checkpoints:

• Batch-specific COAs from an ISO 17025-accredited laboratory with method specification (GC-FID or HPLC-UV at 260nm for nicotine assay)
• Full minor alkaloid profile quantification across consecutive batches: nornicotine, anabasine, anatabine, and myosmine reported individually, not as a combined total
• Heavy metal testing to ICH Q3D limits with individual values reported for lead, arsenic, cadmium, and mercury (not pass/fail only)
• Residual solvent data compliant with ICH Q3C, with the specific extraction method documented
• Chain-of-custody documentation from tobacco source through nicotine extraction and purification
• ISO 9001, HACCP, and GMP-compliant manufacturing processes at the production facility
• Willingness to support a Tobacco Product Master File or provide equivalent documentation for PMTA reference

The risks of unverified suppliers extend beyond quality defects. A supplier who fails an audit mid-production is a supply chain crisis. A supplier whose documentation cannot support your PMTA filing is a regulatory crisis. Both categories of failure are more expensive than the cost of qualifying a supplier who can demonstrate compliance upfront.

The Documentation Gap Most Applicants Discover Late

One of the most consistent patterns in deficient PMTA submissions is the nicotine ingredient documentation gap. The FDA's deficiency letter process reveals what the agency considers insufficient: missing batch-specific data, gaps in impurity characterization, unverified traceability claims, and inconsistency between the nicotine ingredient as described in the application and the COA data on file.

The gap usually traces to a sourcing decision made before the PMTA process began. A manufacturer who selected their nicotine supplier based on price and availability, without verifying the documentation package against PMTA requirements, discovers the gap when it is expensive to fix. Replacing a nicotine supplier mid-development means new stability studies, new manufacturing controls validation, and a significantly delayed application timeline.

The manufacturers who successfully navigated the first PMTA pilot round qualified their ingredient suppliers early. They received documentation packages that supported their filings rather than requiring supplemental requests. That preparation gap is not visible in the authorization data, but it is the single largest driver of application timeline differences between manufacturers at similar stages of development.

Practical Steps for Manufacturers Now

If your PMTA is in preparation or you are planning to file within the next two years, these steps address the ingredient documentation risk before it becomes a deficiency:

1. Request batch-specific COAs from your current supplier for the last five consecutive production batches. If the data shows inconsistency in minor alkaloid content or purity values, that is a materials characterization issue that needs to be addressed before, not during, FDA review.

2. Verify the extraction and purification process is documented. Can your supplier provide a process description that identifies the tobacco source, extraction method, purification steps, and analytical controls applied at each stage? If not, you have a traceability gap.

3. Ask about TPMF filing capability. If your supplier has not filed or is not willing to file a Tobacco Product Master File, understand what that means for your application. You will need to disclose ingredient information in your PMTA that your supplier may consider proprietary. Having that conversation before you file is better than discovering the conflict when you are assembling the application.

4. Confirm heavy metal and residual solvent testing methods. "We test for heavy metals" is not sufficient. "We test per ICH Q3D using ICP-MS with the following method, and here are the last five batch results" is sufficient.

These questions have specific answers, and a qualified supplier should be able to produce them on request.

NicAlliance is a US-based supplier offering 99.5%+ purity freebase nicotine (USP/EP-grade), nicotine salts, and nicotine bitartrate dihydrate with STC chain-of-custody traceability and batch-specific COAs from accredited laboratories. If you want to verify your current supplier against these criteria before filing, NicAlliance can provide batch-specific COAs, a TPMF filing overview, and a documentation gap assessment. Request a sample package or start the conversation with the NicAlliance team.

Frequently Asked Questions